1152617-99-6

Basic information

• Product Name: 4-(3-fluoro-2-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(3-fluoro-2-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1152617-99-6
• Molecular Weight: 295.354
• Mol File: 1152617-99-6.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 4-(3-fluoro-2-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-fluoro-2-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester(1152617-99-6)
• EPA Substance Registry System: 4-(3-fluoro-2-hydroxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester(1152617-99-6)

Safety Data

• Hazardous Substances Data: 1152617-99-6(Hazardous Substances Data)

Upstream product

• 1376335-01-1 4-(2-benzyloxy-3-fluoro-phenyl)-1,2,3,6-tetrahydro-pyridine 
• 1036724-55-6 2-benzyloxy-1-bromo-3-fluoro-benzene 
• 2040-89-3 2-bromo-6-fluorophenol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1152618-01-3 2-fluoro-6-piperidin-4-yl-phenol 
• 1269025-19-5 C₁₆H₂₀FNO₃ 
• 1152617-96-3 4-(2-benzyloxy-3-fluoro-phenyl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1152618-01-3 2-fluoro-6-piperidin-4-yl-phenol 
• 1201927-83-4 C₁₇H₁₈FNO 
• 1201927-71-0 C₁₈H₂₀FNO 
• 1376335-27-1 4-(3-fluoro-2-methoxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

RADIOLABELLED mGluR2 PET LIGANDS

The present invention relates to novel, selective, radiolabelled mGluR2 ligands which are useful for imaging and quantifying the metabotropic glutamate receptor mGluR2 in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists

Compounds that are both norepinephrine reuptake inhibitors (NRI) and 5-HT1A partial agonists may have the potential to treat neuropsychiatric disorders including attention deficit hyperactivity disorder (ADHD) and depression. Targeted screening